Stay updated on Clinical Trial: KZR-616 in Active Polymyositis or Dermatomyositis
Sign up to get notified when there's something new on the Clinical Trial: KZR-616 in Active Polymyositis or Dermatomyositis page.
Latest updates to the Clinical Trial: KZR-616 in Active Polymyositis or Dermatomyositis page
- ChecktodayChange DetectedDifference0.5%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.3%
- Check22 days agoChange DetectedNew detailed secondary outcome measures for the treatment of patients with dermatomyositis using zetomipzomib (KZR-616) have been added, including various assessments of disease activity and pharmacokinetic parameters.SummaryDifference46%
- Check30 days agoChange DetectedClinicalTrials.gov is addressing delays in displaying study record information, and the website has been updated to version 2.10.5, replacing the previous version 2.10.3.SummaryDifference1%
- Check44 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3.SummaryDifference0.1%
- Check58 days agoChange DetectedDifference0.7%
Stay in the know with updates to Clinical Trial: KZR-616 in Active Polymyositis or Dermatomyositis
Enter your email address, and we'll notify you when there's something new on the Clinical Trial: KZR-616 in Active Polymyositis or Dermatomyositis page.